Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 14/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7880463 | 1.00 | LHCGR (0.73) | LHCGRPOLBMAPK1NPSR1MEN1 | |
| SCHEMBL7891790 | 0.94 | POLB (0.69) | LHCGRPOLBMAPK1NPSR1MEN1 | |
| SCHEMBL7887722 | 0.91 | MAPK1 (0.72) | LHCGRMAPK1NPSR1 | |
| SCHEMBL7891804 | 0.89 | LHCGR (0.64) | LHCGRPOLBMEN1KMT2A | |
| SCHEMBL7880265 | 0.89 | HHAT (0.65) | LHCGRPOLB | |
| SCHEMBL8226033 | 0.89 | LHCGR (0.59) | LHCGRPOLBMAPK1NPSR1KMT2A | |
| SCHEMBL7880311 | 0.88 | POLB (0.61) | LHCGRPOLBMAPK1MEN1KMT2A | |
| SCHEMBL7888190 | 0.88 | POLB (0.61) | LHCGRPOLBMAPK1NPSR1MEN1 | |
| SCHEMBL7889885 | 0.88 | POLB (0.61) | LHCGRPOLBMAPK1NPSR1MEN1 | |
| SCHEMBL7887404 | 0.87 | MAPK1 (0.66) | LHCGRMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6177443-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2001-01-23 | — | — | US | claimed |
| EP-0973778-A1 | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-01-26 | — | — | EP | claimed |
| WO-1998040385-A1 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-09-17 | — | — | WO | claimed |
| US-11185527-B2 | Methods and compositions relating to steroid hormone receptor-dependent cancers | WAYNE STATE UNIVERSITY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200155501-A1 | METHODS AND COMPOSITIONS RELATING TO STEROID HORMONE RECEPTOR-DEPENDENT CANCERS | WAYNE STATE UNIVERSITY (US) | 2020-05-21 | — | — | US | disclosed |
| US-6177443-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2001-01-23 | — | — | US | disclosed |
| EP-0973778-A1 | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998040385-A1 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185527-B2 | Methods and compositions relating to steroid hormone receptor-dependent cancers | ESRRA, ESRRB, NR3C1 | LHCGR 18/4885POLB 4463/4885MAPK1 3428/4885 |
| US-20200155501-A1 | METHODS AND COMPOSITIONS RELATING TO STEROID HORMONE RECEPTOR-DEPENDENT CANCERS | ESRRA, ESRRB, NR3C1 | LHCGR 15/4885POLB 4532/4885MAPK1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.